Cancer is one of the deadliest diseases, and in most cases, it is detected at a later stage of its progression. Therefore, an early detection of cancer is mandatory that can save millions of lives worldwide. A simple and sensitive method is required to determine a trace level of target protein biomarker in human blood or serum.
We seek cost effective and reliable nanotechnology-based platforms (plasmonic, or fluorescence-based assays) that can-do early detection with a turnaround time of less than 1 hour.
Based on our expertise in nanotechnology, and cancer cell targeting nanoparticles* (Please refer to the patents and publications of Dr. Selvan, Chief Scientist), “Nanosensors-integrated lateral flow assays” are being developed for the detection of low-level cancer biomarker in serum. We believe our approach has a potential application in clinical analysis and diagnosis.